BLCA is an immunogenic tumor type (49), and an in-depth investigation of Eph receptor/EFN ligand family genes in BLCA identified that inactive kinase EPHB6 may be a potential therapeutic target. The gene discussed is EPHB6; the disease is bladder transitional cell carcinoma.